Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11108445 | 0.84 | KMT2A (0.58) | KMT2AL3MBTL1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL941088 | 0.84 | KMT2A (0.54) | KMT2AL3MBTL1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL11874771 | 0.83 | ALDH1A1 (0.51) | KMT2AL3MBTL1ALDH1A1TRPA1MAPK1 | |
| SCHEMBL338575 | 0.82 | KMT2A (0.53) | KMT2AL3MBTL1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL556208 | 0.82 | KMT2A (0.53) | KMT2AL3MBTL1ALDH1A1GSK3BKDM4E | |
| Hydrochloric Acid SCHEMBL7312871 | 0.82 | KMT2A (0.53) | KMT2AL3MBTL1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1983267 | 0.81 | L3MBTL1 (0.51) | KMT2AL3MBTL1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL5740022 | 0.81 | KDM4E (0.52) | KMT2AL3MBTL1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL220517 | 0.79 | KMT2A (0.53) | KMT2AL3MBTL1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL7056764 | 0.79 | HPGD (0.59) | KMT2AL3MBTL1ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6888012-B2 | Reducing an alpha -haloketone compound by asymmetric hydrogen transfer in presence of a group 9 transition metal compound having a substituted or unsubstituted cyclopentadienyl group and an optically active diamine compound | AJINOMOTO CO., INC. (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20040082820-A1 | Hydrogen transfer reduction; useful as intermediate for production of pharmaceuticals/agricultural chemicals | AJINOMOTO CO., INC. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1346972-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE HALOHYDRIN COMPOUND | Ajinomoto Co., Inc. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082820-A1 | Hydrogen transfer reduction; useful as intermediate for production of pharmaceuticals/agricultural chemicals | DHPS, HDHD5, HYPK | KMT2A 2111/4885L3MBTL1 4143/4885ALDH1A1 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.